tralokinumab
- United States
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
Ballerup, Denmark & Madison, N.J., United States: Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable…
Read More » - Business Wire
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis
NOT FOR DISTRIBUTION IN THE UK OR IRELAND If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically…
Read More »